Cabotegravir, a long-acting injectable antiretroviral drug being developed by the National Institute of Allergy and Infectious Diseases (NIAID) as a potential for pre-exposure prophylaxis (PrEP) in patients at risk of catching human immunodeficiency virus (HIV), could be more desirable than Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate), the currently approved PrEP.

Cabotegravir is intended as a two-monthly injection, showing satisfactory protection against catching HIV in a large-scale study ultimately disrupted by the current global Covid-19 pandemic. Read more here.